

Literatur zum Beitrag von Michael P. Hengartner „Antidepressiva gegen Depressionen“, Kerbe 3/2020, Seite 40

- Bala, A., Nguyen, H. M. T., & Hellstrom, W. J. G. (2018). Post-SSRI sexual dysfunction: A literature review. *Sex Med Rev*, 6(1), 29–34. doi:10.1016/j.sxmr.2017.07.002
- Braillon, A., Lexchin, J., Blumsohn, A., & Hengartner, M. P. (2019). The „pharmaceuticalisation“ of life. *BMJ*, 365, i1972. doi:10.1136/bmj.i1972
- Bschor, T., & Kilarski, L. L. (2016). Are antidepressants effective? A debate on their efficacy for the treatment of major depression in adults. *Expert Rev Neurother*, 16(4), 367–374. doi:10.1586/14737175.2016.1155985
- Chouinard, G., & Chouinard, V. A. (2015). New classification of selective serotonin reuptake inhibitor withdrawal. *Psychother Psychosom*, 84(2), 63–71. doi:10.1159/000371865
- Cohen, J. (1994). The earth is round ($p < .05$). *Am Psychol*, 49(12), 997–1003. doi:10.1037/0003-066x.49.12.1103
- Cosci, F., & Chouinard, G. (2020). Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. *Psychother Psychosom*, 1–24. doi:10.1159/000506868
- Davies, J., & Read, J. (2019). A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? *Addict Behav*, 97, 111–121. doi:10.1016/j.addbeh.2018.08.027
- de Vries, Y. A., Roest, A. M., Beijers, L., Turner, E. H., & de Jonge, P. (2016). Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis. *Eur Neuropsychopharmacol*, 26(11), 1752–1759. doi:10.1016/j.euroneuro.2016.09.370
- DGPP (2015). S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depression. Berlin: DGPPN.
- Dowrick, C., & Frances, A. (2013). Medicalising unhappiness: new classification of depression risks more patients being put on drug treatment from which they will not benefit. *BMJ*, 347, f7140. doi:10.1136/bmj.f7140
- Fava, G. A., & Cosci, F. (2019). Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs. *J Clin Psychiatry*, 80(6). doi:10.4088/JCP.19com12794
- Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015). Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review. *Psychother Psychosom*, 84(2), 72–81. doi:10.1159/000370338
- Goodwin, G. M., & Nutt, D. (2019). Antidepressants; what's the beef? *Acta Neuropsychiatr*, 31(1), 59–60. doi:10.1017/neu.2019.4
- Healy, D. (2018). Citizen petition: Sexual side effects of SSRIs and SNRIs. *Int J Risk Saf Med*, 29(3–4), 135–147. doi:10.3233/IJRS-180745
- Healy, D. (2020). Antidepressants and sexual dysfunction: a history. *J R Soc Med*, 113(4), 133–135. doi:10.1177/0141076819899299
- Hengartner, M. P. (2017). Methodological flaws, conflicts of interest, and scientific fallacies: Implications for the evaluation of antidepressants' efficacy and harm. *Front Psychiatry*, 8, 275. doi:10.3389/fpsy.2017.00275
- Hengartner, M. P. (2019). Scientific debate instead of beef; challenging misleading arguments about the efficacy of antidepressants. *Acta Neuropsychiatr*, 31(4), 235–236. doi:10.1017/neu.2019.23
- Hengartner, M. P., Davies, J., & Read, J. (2019). Antidepressant withdrawal – the tide is finally turning. *Epidemiol Psychiatr Sci*, 29, e52. doi:10.1017/S2045796019000465
- Hengartner, M. P., Jakobsen, J. C., Sorensen, A., & Ploderl, M. (2020). Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials. *PLoS One*, 15(2), e0229381. doi:10.1371/journal.pone.0229381
- Hengartner, M. P., & Ploderl, M. (2018). Statistically significant antidepressant-placebo differences on subjective symptom-rating scales do not prove that the drugs work: Effect size and method bias matter! *Front Psychiatry*, 9, 517. doi:10.3389/fpsy.2018.00517
- Horowitz, M. A., & Taylor, D. (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms. *Lancet Psychiatr*, 6(6), 538–546. doi:10.1016/S2215-0366(19)30032-X
- Hu, X. H., Bull, S. A., Hunkeler, E. M., Ming, E., Lee, J. Y., Fireman, B., & Markson, L. E. (2004). Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. *J Clin Psychiatry*, 65(7), 959–965. doi:10.4088/jcp.v65n0712
- Hughes, S., Cohen, D., & Jaggi, R. (2014). Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study. *BMJ Open*, 4(7), e005535. doi:10.1136/bmjopen-2014-005535
- Hughes, S., Lacasse, J., Fuller, R. R., & Spaulding-Givens, J. (2017). Adverse effects and treatment satisfaction among online users of four antidepressants. *Psychiatry Res*, 255, 78–86. doi:10.1016/j.psychres.2017.05.021
- Huijbregts, K. M., Hoogendoorn, A., Slottje, P., van Balkom, A., & Batelaan, N. M. (2017). Long-term and short-term antidepressant use in general practice: Data from a large cohort in the Netherlands. *Psychother Psychosom*, 86(6), 362–369. doi:10.1159/000480456
- Ioannidis, J. P. (2008). Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? *Philos Ethics Humanit Med*, 3, 14. doi:10.1186/1747-5341-3-14
- Jakobsen, J. C., Gluud, C., & Kirsch, I. (2019). Should antidepressants be used for major depressive disorder? *BMJ Evid Based Med*. doi:10.1136/bmjebm-2019-111238
- Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Moller, K., . . . Gluud, C. (2017). Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. *BMC Psychiatry*, 17(1), 58. doi:10.1186/s12888-016-1173-2
- Jureidini, J., & Tonkin, A. (2006). Overuse of antidepressant drugs for the treatment of depression. *CNS Drugs*, 20(8), 623–632. doi:10.2165/00023210-200620080-00002
- Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. *PLoS Med*, 5(2), e45. doi:10.1371/journal.pmed.0050045
- Lerner, A., & Klein, M. (2019). Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development. *Brain Communications*, 1(1), fczo25. doi:10.1093/brain-comms/fczo25
- Lorenzen, T., & Bschor, T. (2016). Therapie der Depression – vom Gestern zum Morgen. *DNP – Der Neurologe & Psychiater*, 20(6), 65–73.
- Mars, B., Heron, J., Kessler, D., Davies, N. M., Martin, R. M., Thomas, K. H., & Gunnell, D. (2017). Influences on antidepressant prescribing trends in the UK: 1995–2011. *Soc Psychiatry Psychiatr Epidemiol*, 52(2), 193–200. doi:10.1007/s00127-016-1306-4
- Massabki, I., & Abi-Jaoude, E. (2020). Selective serotonin reuptake inhibitor discontinuation syndrome or withdrawal. *Br J Psychiatry*, 1–4. doi:10.1192/bjp.2019.269
- Maund, E., Tendal, B., Hrobjartsson, A., Jorgensen, K. J., Lundh, A., Schroll, J., & Gotzsche, P. C. (2014). Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. *BMJ*, 348, g3510. doi:10.1136/bmj.g3510
- Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003). Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. *BMJ*, 326(7400), 1171–1173. doi:10.1136/bmj.326.7400.1171
- Michelson, D., Fava, M., Amsterdam, J., Apter, J., Lønborg, P., Tamura, R., & Tepner, R. G. (2000). Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. *Br J Psychiatry*, 176, 363–368.
- Mojtabai, R., & Olfson, M. (2014). National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey. *J Clin Psychiatry*, 75(2), 169–177. doi:10.4088/JCP.13mo8443
- Moncrieff, J. (2018). What does the latest meta-analysis really tell us about antidepressants? *Epidemiol Psychiatr Sci*, 27(5), 430–432. doi:10.1017/S2045796018000240
- Moncrieff, J. (2019). Persistent adverse effects of antidepressants. *Epidemiol Psychiatr Sci*, 29, e56. doi:10.1017/S2045796019000520
- Moncrieff, J., & Cohen, D. (2006). Do antidepressants cure or create abnormal brain states? *PLoS Med*, 3(7), e240. doi:10.1371/journal.pmed.0030240

- Moncrieff, J., & Kirsch, I. (2005). Efficacy of antidepressants in adults. *BMJ*, 331(7509), 155–157. doi:10.1136/bmj.331.7509.155
- Munkholm, K., Paludan-Müller, A. S., & Boesen, K. (2019). Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis. *BMJ Open*, 9(6), e024886. doi:10.1136/bmjopen-2018-024886
- Nutt, D. J., Goodwin, G. M., Bhugra, D., Fazel, S., & Lawrie, S. (2014). Attacks on antidepressants: signs of deep-seated stigma? *Lancet Psychiatry*, 1(2), 102–104. doi:10.1016/S2215-0366(14)70232-9
- Perlis, R. H. (2018). Anxiety about antidepressants. *Am J Psychiatry*, 175(6), 500–501. doi:10.1176/appi.ajp.2018.18040399
- Read, J. (2020). How common and severe are six withdrawal effects from, and addiction to, antidepressants? The experiences of a large international sample of patients. *Addict Behav*, 102, 1–8.
- Read, J., Cartwright, C., & Gibson, K. (2018). How many of 1829 antidepressant users report withdrawal effects or addiction? *Int J Ment Health Nurs*, 27(6), 1805–1815. doi:10.1111/inm.12488
- Read, J., & Williams, J. (2018). Adverse effects of antidepressants reported by a large international cohort: Emotional blunting, suicidality, and withdrawal effects. *Curr Drug Saf*, 13(3), 176–186. doi:10.2174/1574886313666180605095130
- Reisman, Y. (2020). Post-SSRI sexual dysfunction. *BMJ*, 368, m754. doi:10.1136/bmj.m754
- Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. *Biol Psychiatry*, 44(2), 77–87.
- Serretti, A., & Chiesa, A. (2009). Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. *J Clin Psychopharmacol*, 29(3), 259–266. doi:10.1097/JCP.0b013e3181a5233f
- Summerfield, D. (2018). NHS antidepressant prescribing: what do we get for pound266m a year? *BMJ*, 360, k1019. doi:10.1136/bmj.k1019
- Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med*, 358(3), 252–260. doi:10.1056/NEJMs065779
- Vilhelmsson, A. (2013). Depression and antidepressants: a nordic perspective. *Front Public Health*, 1, 30. doi:10.3389/fpubh.2013.00030
- Vinberg, M. (2020). Misinformed, misconducted, misguided and misrepresented meta-analyses. The use of antidepressants (AD) in major depressive disorders (MDD). *Bipolar Disord*. doi:10.1111/bdi.12893
- Wang, S. M., Han, C., Lee, S. J., Jun, T. Y., Patkar, A. A., Masand, P. S., & Pae, C. U. (2018). Efficacy of antidepressants: bias in randomized clinical trials and related issues. *Expert Rev Clin Pharmacol*, 11(1), 15–25. doi:10.1080/17512433.2017.1377070
- Wasserstein, R. L., & Lazar, N. A. (2016). The ASA's statement on p-values: context, process, and purpose. *Am Stat*, 70(2), 129–133. doi:10.1080/00031305.2016.1154108
- Wieseler, B., Wolfram, N., McGauran, N., Kerekes, M. F., Vervolgyi, V., Kohlepp, P., . . . Grouven, U. (2013). Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. *PLoS Med*, 10(10), e1001526. doi:10.1371/journal.pmed.1001526
- Zimmerman, M., Galione, J. N., Attiullah, N., Friedman, M., Toba, C., Boerescu, D. A., & Ragheb, M. (2010). Underrecognition of clinically significant side effects in depressed outpatients. *J Clin Psychiatry*, 71(4), 484–490. doi:10.4088/JCP.08m04978blu